Analysts weighed in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with bullish sentiments following the company’s investor meeting this week.
In a research report released Thursday, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a price …
In a research report released Friday, Needham analyst Alan Carr reiterated a Buy rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and raised the …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and …
In a research report issued yesterday, H.C.
In a research report released Friday, Needham analyst Alan Carr maintained a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $38 price target, after the …
The investment banking firm J.P.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is making headlines with the sudden announcement of the CEO’s retirement and an application delay for the company’s leading drug.
